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Background: Studies in adults with chronic kidney
diseases demonstrate that the orally available angiotensin
II antagonist irbesartan reduces arterial pressure and
pathological proteinuria, mostly with an excellent tolera-
bility profile. Little information is available on irbesartan
in childhood.
Methods: A total of 44 pediatric outpatients with
chronic kidney disease (27 male and 17, aged 3.7 to 18
years, median 10 years) were given irbesartan once a day
during 18 weeks for arterial hypertension (N  23), pro-
teinuria (N  8), or both (N  13).
Results: In patients with hypertension, the use of irbe-
sartan 4.1 (3.1–5.3) mg/kg body weight daily (median and
interquartile range) was associated with a decrease (P 
.005) in arterial pressure by 17 (13–22)/10 (7–12) mm Hg.
In patients with overt proteinuria the urinary protein ex-
cretion decreased (P  .01) during treatment with irbesar-
tan (2.9 [2.0–4.8] mg/kg body weight) by 52 (0–75)
mg/[m2  h]), whereas plasma albumin increased (P 
.05) by 4 (1–5) g/L. The frequency of abdominal pain,
constipation, cough, diarrhea, dizziness, edema, fatigue,
headache, insomnia, myalgia, orthostasis, and rash was
similar before and with irbesartan. Plasma sodium slightly
decreased, whereas plasma potassium increased, with irbe-
sartan (P  .01).
Conclusions: In pediatric patients with chronic kidney
diseases, irbesartan given once a day for 18 weeks signif-
icantly reduces arterial pressure and proteinuria, with an
excellent tolerability and side effect profile. Am J Hy-
pertens 2002;15:1057–1063 © 2002 American Journal of
Hypertension, Ltd.
KeyWords: Irbesartan, chronic kidney disease, hyper-
tension, proteinuria, childhood.
A ngiotensin II receptor blockers, subsequently re-ferred to as angiotensin antagonists, represent aclass of drugs that inhibit the renin-angiotensin
II–aldosterone system by blocking angiotensin II type 1
receptor.1 A number of studies have demonstrated the
efficacy of the angiotensin antagonist irbesartan given once a
day in the treatment of hypertension. As an antihypertensive
agent, irbesartan is as effective as converting enzyme inhib-
itors, thiazide diuretics, -blockers, and calcium channel
blockers, mostly with a better tolerability profile, and at least
as effective as currently available angiotensin antagonists
such losartan, valsartan, and candesartan.2 As with other
angiotensin antagonists, the efficacy of irbesartan is enhanced
by concomitant administration of a diuretic. In combination
with other classes of drugs such as calcium channel blockers
or -blockers, irbesartan is also efficacious in the treatment of
moderate to severe arterial hypertension.2 Finally, studies in
patients with chronic kidney diseases have shown that irbe-
sartan reduces pathologic proteinuria and mitigates the dis-
ease progression.3–5
Antihypertensive drugs are not usually investigated in
children before approval for marketing in adulthood, and
information is mostly acquired during clinical use, with
initial doses established by extrapolations from doses in
adults.6 The purpose of the present report is to describe the
experience with the angiotensin antagonist irbesartan
given for 18 weeks in 44 pediatric outpatients with chronic
kidney diseases.
Patients and Methods
Arterial Hypertension
Thirty-six pediatric outpatients (22 male and 14 female,
aged 3.7 to 18 years, median 10 years) with arterial hy-
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pertension were prospectively evaluated in Berne and Mi-
lan between 1999 and 2001. The underlying renal condi-
tions were glomerular diseases (N  13), urinary tract
malformations (N  12), polycystic kidney disease (N 
3), nephronophthisis (N  1), renal artery stenosis (N 
1), and renal transplant (N  6). Renal function7 was
normal (normal plasma creatinine for age and sex, N 
16), mildly reduced (plasma creatinine increased but177
mol/L; N  8) or moderately reduced (plasma creatinine
178 to 354 mol/L, N  7). Five patients were on regular
dialysis (hemodialysis, N  1; home peritoneal dialysis, N
 4). In the patients, sitting arterial pressure was persis-
tently above the centile 95 for age, body length, and sex.8
Of the 36 patients, 12 subsequently referred to as “pre-
treated” were on medication with a variety of antihyper-
tensive agents (diuretics, N  5; diuretics associated with
amlodipine, N  3; amlodipine, N  2; atenolol, N  2).
The regularly scheduled antihypertensive regimen had not
been changed for at least 6 weeks and was not modified
during treatment with irbesartan. The remaining 24 pa-
tients, subsequently referred to as “unpretreated,” were not
on antihypertensive drugs. Before irbesartan administra-
tion, arterial hypertension was either mild (systolic value
19 mm Hg or diastolic value 9 mm Hg above centile
95, N  8), moderate (systolic value 20 to 39 mm Hg or
diastolic value 10 to 19 mm Hg above centile 95, N 11),
or severe (systolic value39 mm Hg or diastolic value 19
mm Hg above centile 95, N  17).9 Irbesartan was deliv-
ered once a day by commercially available tablets (75,
150, and 300 mg), starting with a dose of 37.5 (body
weight ranging 10 to 20 kg), 75 (body weight 21 to 40 kg),
or 150 mg (body weight40 kg) on awakening.9 The dose
of irbesartan was doubled if there was failure to decrease
systolic arterial pressure 10 mm Hg 3 to 5 weeks after
starting irbesartan, or if systolic arterial pressure was
above the centile 95 for body length and sex 8 to 12 weeks
after starting irbesartan. Arterial pressure, heart rate, and
body weight were measured, and blood was taken for the
determination of packed cell volume (microhematocrit
centrifuge), sodium and potassium (ion selective elec-
trodes), creatinine (kinetic alkaline picrate assay), uric
acid (allantoin-uricase assay), albumin (bromcresol purple
assay), and aminotranferases and creatine kinase (kinetic
assays) from each patient before entering the trial and after
18 weeks of irbesartan. The whole blood cyclosporine
trough level was measured using a specific monoclonal
fluorescent polarization immunoassay in the patients
treated with this agent. Patients were monitored by a
written questionnaire before and during irbesartan treat-
ment for the presence of abdominal pain, constipation,
cough, diarrhea, dizziness, edema, fatigue, headache, in-
somnia, myalgia, nausea, orthostasis, and rash. Sitting
(10 min) arterial pressure (first and fifth Korotkoff
sounds) was measured after overnight by means of a
mercury sphygmomanometer with a cuff covering approx-
imately three quarters of the upper arm length from the
acromion to the olecranon; each recorded value was the
mean of at least three consecutive measurements. The
effect of irbesartan on arterial pressure was evaluated 24 h
postdose.
Overt Proteinuria
Twenty-one outpatients (12 male and 9 female subjects,
aged between 4.8 and 14, median 10 years) with overt
proteinuria, defined as urinary protein excretion 6 mg/
[m2  h], were prospectively evaluated. They were 13 of
the aforementioned patients with arterial hypertension
(glomerular diseases, N  12; nephronophthisis, N  1;
see Arterial Hypertension) and eight normotensive pa-
tients (five male and three female subjects, aged 4.1 to 14
years, median 12 years) with chronic glomerular diseases.
Renal function was either normal (N  16) or mildly
reduced (N  5).
Irbesartan was given at a once-a-day dose of 37.5 (body
weight ranging between 10 and 20 kg), 75 (body weight
between 20 and 40 kg) or 150 mg (body weight 40 kg)
on awakening during 18 weeks. In the eight normotensive
patients with pathologic proteinuria, the dose of irbesartan
was not further increased during the study. Arterial pres-
sure, heart rate, body weight, laboratory values, and the
written questionnaire were evaluated as in patients with
arterial hypertension. In addition, every patient carried out
a timed overnight urine collection during 3 consecutive
days both before and with irbesartan for determination of
total protein (Coomassie blue assay) and creatinine (kinet-
ic alkaline picrate assay). The urinary protein excretion (in
mg/[m2  h]) and the urinary protein/creatinine ratio (in
mg/mmol) were calculated. The mean of the three deter-
minations was used for analysis.
Data Analysis
None of the patients included in this report was enrolled in
a preliminary communication published earlier by some of
us.9 The study protocol had been approved by the local
Ethics Committees and by the participants. Female sub-
jects of childbearing potential were excluded from the trial
because of the possible fetal and neonatal toxicity. Pill
count and pharmacy records were used to assess adherence
to prescribed irbesartan. The length–weight equation de-
veloped by Haycock et al was used to estimate body
surface area.10 Results are given as median and interquar-
tile range (which extends from the value at centile 25 to
that at centile 75 and includes half of the data points), as
relative frequency, or depicted as a “box and whiskers
plot” (boxes are median and interquartile ranges, vertical
lines are ranges). Nonparametric analysis of variance for
repeated measurements, the McNemar change test (with
the Yates correction for continuity), and simple regres-
sions with the coefficient of correlation rs2 were used for
analysis. A P value  .05 was regarded as statistically
significant.
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Results
Characteristics of the Patients
The age distribution of the 44 patients and the correspond-
ing disease conditions are shown in Fig. 1.
Tolerability and Side Effect Profile
A 12-year-old normotensive boy with pathologic protein-
uria reported the appearance of elevated, erythematous
pruritic wheals surrounded by an area of erythema involv-
ing the head and the trunk 2 h after a first dose of
irbesartan. Swelling of the mouth, tongue, and eyelids was
not reported. As a consequence, he withdrew from irbe-
sartan. In the remaining patients, the frequency of abdom-
inal pain, constipation, cough, diarrhea, dizziness, edema,
fatigue, headache, insomnia, myalgia, orthostasis, and rash
was similar before and during irbesartan treatment (Table
1). Hence, no further patient withdrew from irbesartan.
Plasma sodium slightly but significantly decreased,
whereas plasma potassium significantly increased. Packed
cell volume, plasma aminotransferases, creatine kinase,
creatinine, and uric acid were not influenced by the use of
irbesartan. In none of the patients did plasma potassium
and sodium levels change by0.5 mmol/L and 5 mmol/L.
In none of the patients did circulating uric acid and cre-
atinine levels change by 20% (Table 2).
FIG. 1. Age distribution and disease conditions in 44 pediatric pa-
tients with chronic kidney diseases (27 male and 17 female sub-
jects) included in the study.
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Hypertension
Before irbesartan, arterial pressure was 152 (142–166)/92
(85–96) mm Hg in the 36 patients with arterial hyperten-
sion. The initial irbesartan dose of 2.6 (2.2–2.9) mg/kg
body weight once a day (71 [59–102] mg/m2 body surface
area once a day) was doubled in 26 of the 36 patients. At
the end of the study, the dose of irbesartan was 4.1
(3.1–5.0) mg/kg (113 [98–168] mg/m2 body surface area)
once a day in the 36 hypertensive patients. The use of
irbesartan for 18 weeks was associated with a decrease (P
 .005) in arterial pressure by 17 (13–22)/10 [7–12] mm
Hg up to 136 [128–148]/ 83 [79–87] mm Hg (Fig. 2). At
that time, both systolic and diastolic blood pressure were
below centile 95 in 20 of the 36 patients with arterial
hypertension. Plasma albumin (38 [36–40] v 39 [36–41]
g/L), heart rate (80 [74–83] v 76 [70–84]/min), body
weight (33.1 [23.6–50.0] v 33.8 [23.8–49.9] kg), and
body surface area (1.19 [0.93–1.40] v 1.20 [0.94–1.40]
m2) were similar before and with irbesartan. The effect of
irbesartan on arterial pressure (20 [15–22]/9 [7–11] v 16
[11–22]/10 [7–13] mm Hg) and its dose (4.1 [3.1–4.9] v
4.0 [3.1–5.2] mg/kg body weight once a day) were not
statistically different in 16 patients with normal renal func-
tion and in the remaining 20 patients. Furthermore, the
effect on arterial pressure was similar in “pretreated” (18
[11–22] mm Hg; N 12) and “nonpretreated” (16 [13–22]
mm Hg; N  24) patients. Linear regression analysis
failed to disclose any relationship between patient age and
final irbesartan dose, expressed either in mg/kg body
weight daily or in mg/m2 body surface area daily. Further
regression analysis failed to demonstrate a significant re-
lationship between irbesartan doses, expressed either in
mg/kg body weight daily or in mg/m2 body surface area
daily, and change in arterial pressure. Finally, no signifi-
cant correlation was noted between patient age and the
influence of irbesartan on arterial pressure.
Proteinuria
Before irbesartan treatment, urinary protein excretion
ranged from 51 to 204, median 126 mg/(m2  h) in the 20
patients with overt proteinuria who completed the study.
The urinary protein excretion was similar in patients with
(144 [89–150] mg/[m2  h]) and without (101 [74–129]
mg/[m2  h]) arterial hypertension. In the 20 patients,
overnight urinary protein significantly decreased during
treatment with irbesartan by 52 (0–75) mg/(m2  h) (P 
.01), whereas plasma albumin significantly (P  .05)
increased by 4 [1–5] g/L: from 29 [21–30] to 33 [24–35]
g/L, as depicted in Fig. 3. Urinary protein excretion de-
creased by 25%, namely, from 27% to 93% in 13 of the
20 patients with overt proteinuria.
A very close correlation was noted between the urinary
protein excretion (in mg/[m2  h]), taken as an indepen-
dent value, and the urinary protein/creatinine ratio (in
mg/mmol), taken as a dependent value: y  5.02 ; rs2 
0.82, P .0001). In the seven patients with proteinuria but
without hypertension who completed the study, the irbe-
sartan dose was 2.9 (2.0–4.8) mg/kg body weight once a
day (74 [62–127] mg/m2 body surface area). In these
patients, arterial pressure was similar before (114 [101–
120]/63 [57–70]) and during (112 [98–118]/60 [55–70])
irbesartan treatment.
Interaction With Cyclosporine
In the eight patients treated with cyclosporine, the dose
and the trough level of this agent were stable throughout
the trial, as shown in Table 3.
Discussion
Adherence to the recommended regimen of care and per-
sistence with it over time are common concerns in medical
practice. Observations in adults indicate that in one half of
Table 2. Laboratory safety values (median and interquartile range) before and with irbesartan in 43
pediatric patients with chronic kidney diseases
Hypertension Without Proteinuria Hypertension With Proteinuria
Patients, N 23 23 13 13
Packed cell volume, L/L 0.39 (0.36–0.42) 0.39 (0.36–0.41) 0.40 (0.39–0.42) 0.39 (0.38–0.41)
Plasma aspartate
aminotransferase, U/L 35 (24–36) 28 (20–36) 24 (22–36) 25 (24–36)
Plasma alanine
aminotransferase, U/L 24 (13–31) 24 (14–32) 15 (12–30) 13 (12–24)
Plasma creatine kinase, U/L 85 (45–145) 84 (42–130) 55 (28–126) 55 (26–135)
Plasma sodium, mmol/L 139 (136–140) 137* (135–139) 138 (135–140) 136 (135–139)
Plasma potassium, mmol/L 4.2 (4.0–4.5) 4.4* (4.2–4.6) 3.9 (3.6–4.0) 4.1 (3.9–4.4)
Plasma creatinine, mol/L 76 (65–85) 75 (65–83) 74 (56–94) 70 (65–80)
Plasama uric acid acid,
mol/L 388 (267–420) 378 (280–434) 331 (275–368) 347 (265–378)
Values noted in the patient who withdrew from the study are not given.
* P  .03 and †P  .01 v before irbesartan.
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individuals with hypertension, arterial pressure is con-
trolled, and one half of them stop taking their drugs during
the initial year of treatment. Persistence varies with indi-
vidual drugs, and adverse effects are the primary culprits.
Adherence to the recommended antihypertensive regimen
is also better in patients who are prescribed fewer drugs.11
The present experience in pre–school-aged children, older
children, and male adolescents with chronic kidney dis-
eases given irbesartan for 18 weeks in a dose of approx-
imately 4 mg/kg body weight (or 110 mg/m2 body surface
area) confirms the results of large trials in hypertensive
adults treated with this drug, which blocks the binding of
angiotensin II to type 1 angiotensin receptors. The major
consistently observed advantages of irbesartan and other
angiotensin antagonists are outstanding tolerability, low
side effect profile, and use on a once-a-day basis.1–5 Fur-
thermore, the present limited experience confirms the abil-
ity of this drug to reduce overt proteinuria, a recognized
surrogate marker of the efficacy of drugs in retarding the
progression of kidney disease.3–5
This discussion will first focus on the antihypertensive
and antiproteinuric effectiveness and the safety of irbesar-
tan in this study. Despite the statistically significant and
clinically relevant decrease in arterial pressure, irbesartan
failed to normalize blood pressure in a large proportion
(44%) of our hypertensive patients with chronic kidney
diseases. This observation is probably related to the fact
that arterial hypertension was moderate to severe in ap-
proximately 80% of the patients included in the survey.
Hypertension and proteinuria are the most important fac-
tors that modulate progression in chronic kidney diseas-
es.12 Antihypertensive drugs mitigate progression, and this
has been traditionally attributed to their blood pressure
lowering action. It is agreed, however, that in chronic
kidney diseases, angiotensin converting enzyme (ACE)
inhibitors are superior to other drugs.12 One limiting ad-
verse effect in a minority of patients given ACE inhibitors
is cough, an effect that does not occur with angiotensin
antagonists.13,14 Data in adult patients with kidney dis-
eases have shown that angiotensin antagonists are as ef-
fective as ACE inhibitors in reducing pathologic protein-
uria and slowing disease progression.15 In the present
study, treatment with irbesartan was associated with sta-
tistically significant but clinically irrelevant decreases in
circulating sodium and increases in circulating potassium.
However, no tendency toward higher circulating creatinine
was observed. Hyponatremia, hyperkalemia, or renal fail-
ure have been previously reported in adults given angio-
tensin antagonists and in children and adults given ACE
inhibitors. The effect on circulating sodium and potassium
results from the suppression of the secretion of aldosterone
driven by angiotensin II. In conditions in which glomeru-
lar filtration rate is critically dependent on angiotensin II
(such as bilateral renal artery stenosis, heart failure, or
volume depletion), blockade of the renin–angiotensin II–
aldosterone system with either ACE inhibitors or angio-
tensin II antagonists can induce acute renal failure.1
The very attractive pharmacokinetic properties of irbe-
sartan include an almost complete intestinal absorption of
approximately 80% that is not affected by food, and a long
elimination half-time of approximately 15 h that is not
significantly altered by the presence of kidney disease.
Furthermore, irbesartan does not require biotransformation
for its pharmacologic activity.1,2 Finally, our experience in
patients concurrently treated with cyclosporine confirms
data indicating that there are no interactions between irbe-
sartan and other drugs.16 In this pediatric study, the anti-
hypertensive properties of irbesartan and its doses were
age independent but were body weight and body surface
area dependent.1,2 These data provide support to a small,
very recent study indicating that the pharmacokinetics of
Table 2. (continued)
Proteinuria Without Hypertension All Patients
7 7 43 43
0.40 (0.39–0.41) 0.39 (0.37–0.42) 0.39 (0.36–0.42) 0.39 (0.35–0.41)
30 (25–36) 29 (24–30) 25 (24–36) 28 (20–36)
20 (14–32) 24 (15–31) 18 (12–31) 20 (12–31)
34 (27–82) 34 (27–80) 55 (33–145) 55 (31–130)
139 (138–140) 138 (137–139) 138 (136–140) 137† (135–139)
4.2 (4.0–4.6) 4.3 (4.1–4.6) 4.1 (3.9–4.5) 4.3† (4.1–4.6)
78 (67–87) 77 (73–81) 76 (61–85) 75 (65–83)
286 (258–347) 301 (250–359) 331 (269–420) 335 (265–434)
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irbesartan is similar between children aged 6 to 18 years
and adults.17
Like ACE inhibitors, angiotensin antagonists reduce
the activity of the renin–angiotensin II–aldosterone sys-
tem. Nonetheless, there are two differences: the receptors
that are affected, and the effect on kinins.18,19 Angiotensin
II activates both type 1 and type 2 receptors. As a result,
inhibition of angiotensin II formation with an ACE inhib-
itor will diminish the activity of both receptor types. In
contrast, angiotensin antagonists diminish only type 1
activity. The type 1 receptor mediates the vasoconstrictor
effect of angiotensin II and is generally thought to mediate
angiotensin II–induced growth in the ventricle and the
arterial wall. Several recent studies suggest that the type 2
receptor exerts the opposite effects from the type 1 recep-
tor. For example, activation of the type 2 receptor exerts
antigrowth, antihyperthrophic, proapoptotic, and hypoten-
sive effects. Angiotensin converting enzyme is also a ki-
ninase. As a result, inhibiting this enzyme with an ACE
inhibitor increases kinin levels, an effect not observed with
angiotensin antagonists. It is presumed that the absence of
kinin accumulation accounts for the lack of cough with
angiotensin antagonists. However, kinin accumulation
may also mediate some of the beneficial effects of ACE
inhibition. At this time, it remains unclear whether angio-
tensin antagonists are a minor addition (an ACE inhibitor
without cough) or a major advance. Outcome data are
needed before angiotensin II receptor blockers are gener-
ally recommended instead of ACE inhibitors.1
Limitations of the present study include its uncontrolled
design and the lack of a comparison agent. More impor-
tantly, the impact of angiotensin antagonists on progres-
sion of chronic kidney disease and on target organ damage
in childhood cannot be established from our data. It is
worthy of mention, however, that this statement also holds
true for the remaining classes of antihypertensive drugs
that are widely used in childhood.6 Large trials performed
in adult patients demonstrate the benefits of diuretics,
-blockers, ACE inhibitors, and angiotensin II receptor
blockers on target organ damage.20 On the contrary, the
results of large trials demonstrate that postsynaptic 1-
receptor blockers, direct vasodilators, and perhaps even
FIG. 2. Systolic and diastolic arterial pressure before and with irbe-
sartan in 36 hypertensive patients with chronic kidney diseases.
Both systolic and diastolic arterial pressure were significantly lower
with irbesartan (P  .005). Results are given as “box and whiskers
plot.” In this plot, boxes are median and interquartile ranges, and
vertical lines are ranges.
FIG. 3. Urinary protein excretion before and with irbesartan in 20
pediatric patients with overt proteinuria.
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some dihydropyridine calcium channel blockers do not
positively influence the long term outcome.9,21
In conclusion, we believe that, despite these limitations,
the present data indicate that irbesartan is an effective and
very well tolerated agent for the management of chronic
kidney diseases in children.
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Table 3. Dosage and trough blood levels of cyclosporine in 8 pediatric patients (5 boys and 3 girls, aged 4.8
to 18 years, median 9.4 years) with chronic kidney diseases before and with irbesartan
Before Irbesartan With Irbesartan P Value
Cyclosporine dosage, mg/kg daily* 4.5 (4.0–5.1) 4.4 (4.0–5.0) NS
Cyclosporinemia, g/l 121 (85–159) 130 (101–152) NS
NS  not significant.
Results are given as median and interquartile range.
* Given in two daily doses.
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